** Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket
** AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments
** Symbravo is a combination of two medicines, meloxicam and rizatriptan
** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says
** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women
** AXSM gained 6.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。